Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Bone Miner Res. 2017 Aug 25;32(10):2062–2073. doi: 10.1002/jbmr.3197

Figure 1. Human 72aa FGF23 C-tail Fc fusion has an inhibitory potency similar to the human 72aa FGF23 C-tail peptide.

Figure 1

(A) IC50s derived for both the FGF23 c-tail peptide and Fc fusion based on luciferase activity from a HEK293-klotho-Egr1 reporter cell line using increasing amounts of either FGF23 c-tail peptide or FGF23 c-tail Fc prior to stimulating cells with sub-saturating amounts of recombinant FGF23 (B) IC50s derived from competitive binding assessment in HEK293-klotho lines using the MFI from individual samples of increasing amounts of either FGF23 c-tail peptide or Fc followed by binding of sub-saturating amounts of FGF23. Data representative of n=3.